

## MEMORANDUM

---

**DATE:** January 19, 2022

**FROM:** Dr. Eric Partlow, Infectious Diseases Consultant, Department of Medicine, Island Health

**RE:** Sotrovimab Therapy for Vulnerable Patients

---

New COVID-19 therapies are now available for the treatment of outpatients with mild to moderate illness who are at high risk for progression to hospitalization and severe disease. Island Health has established an **Outpatient Covid Therapeutics Clinic (OCTC)** for the evaluation and treatment of patients who meet criteria for these therapies. Sotrovimab is a newly approved intravenous monoclonal antibody therapy, which has been shown to significantly reduce the risk of hospitalization in high risk patients. To be effective, the drug must be given early in the course of illness, within 7 days of symptom onset. Beginning January 10, 2022, sotrovimab will be administered intravenously at 3 outpatient clinics in Island Health at the Royal Jubilee, Nanaimo Regional, and Campbell River Hospitals.

### Patient Eligibility

To meet criteria patients must have a positive Covid test, they must present within 7 days of symptom onset, and they need to be in one of the following high risk Tier one populations to qualify for therapy.

1. Patients identified as **Clinically Extremely Vulnerable Group 1 and Group 2 (CEV 1 and CEV 2)**, regardless of vaccine status or previous infection. They are considered unlikely to respond to vaccination. (Treatment may be offered despite >7 days of symptom onset based on clinical judgement)
  - a. Active treatment for solid tumor or hematological malignancies
  - b. Having received a solid organ transplant treated with immunosuppression
  - c. Receiving CAR-T cell therapy or hematopoietic stem cell transplant in the last 2 yrs,
  - d. Having a moderate to severe primary immunodeficiency
  - e. Having advanced untreated HIV or AIDS
  - f. Active receipt of anti-B cell therapies (e.g. rituximab, ocrelizumab, obinutuzumab), high-dose systemic steroids (=20mg prednisone equivalent daily for at least 14 days), alkylating agents (e.g. cyclophosphamide, cisplatin), antimetabolites (e.g. methotrexate, 5-FU) or anti-TNF agents (e.g. infliximab, adalimumab).
  - g. Those with ESRD on dialysis
2. Unvaccinated or partially vaccinated individuals identified as **Clinically Extremely Vulnerable Group 3 (CEV3)**. (less than 2 doses of vaccine or 2 doses of non-mRNA vaccine)
  - a. This includes a heterogeneous group of disorders including patients with severe respiratory conditions, rare blood disorders and hematologic diseases and cancers,, splenectomy, metabolic disorders, significant developmental disabilities, and milder immune suppression.
  - b. Pregnancy
  - c. Diabetes requiring insulin therapy

Excellent health and care, for  
everyone, everywhere, everytime.



3. Unvaccinated or partially vaccinated individuals **aged  $\geq 70$  years with one or more chronic condition/co-morbidity** (e.g. obesity, non-insulin dependent diabetes, hypertension, heart failure, renal dysfunction) (Many chronic conditions or comorbidities can be considered; consult a clinician for guidance as this list is not exhaustive)
4. Unvaccinated (and previously uninfected) or partially vaccinated **individuals  $\geq 60$  years with three or more chronic conditions/co-morbidities**
5. Unvaccinated (Previously uninfected) or partially vaccinated **aboriginal individuals  $\geq 60$  years** .

### Active screening and patient referral

The OCTC will actively screen new positive Covid patients on a daily basis. However, it is impossible to detect every potential patient with this mechanism and some patients will need to contact us directly for assessment. Vulnerable patients in your practice should be made aware of these new treatments and if they test positive for COVID-19 we invite them to refer to the [website](#) to review eligibility criteria and contact the clinic directly if they feel they are potential candidates for therapy.

### OCTC contact information and Resources

Island Health website:

<https://www.islandhealth.ca/learn-about-health/covid-19/outpatient-covid-19-therapeutics-clinic>

To book an appointment: 250-737-2030, extension 44685.

### *Clinical Practice Guide for the Use of Sotrovimab in Patients with COVID-19:*



ClinicalPracticeGuide  
\_Sotrovimab.pdf

### *Patient information sheet:*



OCTC Sotrovimab  
Information Sheet Fin